Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Wednesday, October 5, 2016

NICE Planning to Reject MS Treatment, Zinbryta, in England and Wales


                                                                  
  

Click here to receive MS news via e-mail


The National Institute for Health and Care Excellence (NICE), the health authority for England and Wales, has decided not to recommendZinbryta (daclizumab) to be available to multiple sclerosis (MS) patients through the country’s health service. The decision came in a first stage of the drug’s review process, and NICE is welcomingfeedback from patient groups, healthcare professionals, and others.
In making this initial decision, NICE reported that issues linked to the clinical and cost-effectiveness models presented by Zinbryta’s developer, Biogen, presented a high degree of uncertainty. Biogen has been asked to submit further evidence.
“The committee concluded that daclizumab was not cost effective for patients without more active disease … [and]  that it had not been presented with robust evidence that daclizumab was cost effective for people with more active disease … Because the committee considered the analyses to be highly uncertain or not relevant to the NHS [National Health System], it invited the company to submit revised analyses,”NICE concluded in its report.




MS Views and News
Providing educational information, resources and services for those affected by MS





No comments: